HomeCompareCYJBY vs JNJ

CYJBY vs JNJ: Dividend Comparison 2026

CYJBY yields 3.26% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYJBY wins by $624.50M in total portfolio value
10 years
CYJBY
CYJBY
● Live price
3.26%
Share price
$24.39
Annual div
$0.79
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$624.53M
Annual income
$589,743,767.41
Full CYJBY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CYJBY vs JNJ

📍 CYJBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYJBYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYJBY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYJBY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYJBY
Annual income on $10K today (after 15% tax)
$276.87/yr
After 10yr DRIP, annual income (after tax)
$501,282,202.30/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CYJBY beats the other by $501,278,216.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYJBY + JNJ for your $10,000?

CYJBY: 50%JNJ: 50%
100% JNJ50/50100% CYJBY
Portfolio after 10yr
$312.28M
Annual income
$294,874,228.40/yr
Blended yield
94.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CYJBY
No analyst data
Altman Z
5.3
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYJBY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYJBYJNJ
Forward yield3.26%2.13%
Annual dividend / share$0.79$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$624.53M$30.3K
Annual income after 10y$589,743,767.41$4,689.40
Total dividends collected$621.98M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CYJBY vs JNJ ($10,000, DRIP)

YearCYJBY PortfolioCYJBY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,351$651.45$10,592$272.30+$759.00CYJBY
2$13,528$1,382.22$11,289$357.73+$2.2KCYJBY
3$17,554$3,079.03$12,123$472.89+$5.4KCYJBY
4$26,251$7,467.94$13,141$629.86+$13.1KCYJBY
5$48,963$20,874.22$14,408$846.81+$34.6KCYJBY
6$125,164$72,774.08$16,021$1,151.60+$109.1KCYJBY
7$481,652$347,725.89$18,122$1,588.22+$463.5KCYJBY
8$3,016,495$2,501,127.86$20,930$2,228.20+$3.00MCYJBY
9$32,506,342$29,278,692.16$24,792$3,191.91+$32.48MCYJBY
10$624,525,553$589,743,767.41$30,274$4,689.40+$624.50MCYJBY

CYJBY vs JNJ: Complete Analysis 2026

CYJBYStock

Cargotec Corporation provides cargo and load handling solutions worldwide. It operates in three segments: Kalmar, Hiab, and MacGregor. The Kalmar segment offers cargo handling equipment and automated terminal solutions, software, and services for ports, terminals, distribution centers, and various industries; ship-toshore cranes, rubbertyred and rail-mounted gantry cranes, straddle and shuttle carriers, reachstackers, empty container handlers, terminal tractors, and forklift trucks, and automated guided vehicles; and automation systems, and Bromma spreaders, as well as maintenance contracts, technical support, spare parts, training, and crane upgrade services. The Hiab segment provides loader handling equipment under the HIAB, EFFER, and ARGOS brands; truck mounted forklifts under the MOFFETT and PRINCETON brands; forestry and recycling cranes under the LOGLIFT and JONSERED brands; hooklifts and skiploaders under the MULTILIFT brand; tail lifts under the ZEPRO, DEL, and WALTCO brands; HiConnect platform; and Hiab ProCare services and HiVision crane operating system. The MacGregor segment offers cargo and load handling solutions and maintenance services. Cargotec Corporation was incorporated in 2005 and is headquartered in Helsinki, Finland.

Full CYJBY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CYJBY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYJBY vs SCHDCYJBY vs JEPICYJBY vs OCYJBY vs KOCYJBY vs MAINCYJBY vs ABBVCYJBY vs MRKCYJBY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.